Content related to Long-Term Neurocognitive Effects Linked to Chemotherapy-Induced Hearing Loss

Researchers at Children’s Hospital Los Angeles led a multi-institutional study that pins down, for the first time, the actual risk of hearing loss from cisplatin, a common chemotherapy agent

Patients with acute lymphoblastic leukemia are at increased risk for bone fractures due to bone loss resulting from treatment. This decrease in bone density (as illustrated here) can occur as soon as

Opsoclonus-Myoclonus Syndrome or OMS (also known as the “dancing eyes” syndrome) affects roughly 1 in every 200 patients with neuroblastoma, a cancer of the sympathetic nervous system.

A team of researchers from nine leading academic hospitals and research centers have published a paper in the early online edition of the journal Cancer that describes pulmonary outcomes among

Investigators from Children’s Hospital Los Angeles and 37 other Children’s Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing

Risk of detecting cancer cells decreased by 70% after one month of treatment

A CHLA oncologist led a pivotal clinical trial leading to the approval of the first drug to prevent cisplatin hearing loss in children.

Cultured retinoblastoma tumor containing tumor cells (red) and fibroblasts (green). Researchers at The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) have demonstrated that